# Trial to Reduce Insulin-dependent diabetes mellitus in the Genetically at Risk

Submission date Recruitment status Prospectively registered 26/09/2005 No longer recruiting [X] Protocol [ ] Statistical analysis plan Registration date Overall study status 26/09/2005 Completed [X] Results Individual participant data **Last Edited** Condition category 12/04/2019 Nutritional, Metabolic, Endocrine

#### Plain English summary of protocol

Not provided at time of registration

# **Contact information**

## Type(s)

Scientific

#### Contact name

Dr John Dupre

#### Contact details

John P. Robarts Research Institute PO Box 5015 100 Perth Dr. London Canada N6A 5K8 +1 519 663 2935 john.dupre@lhsc.on.ca

## Additional identifiers

ClinicalTrials.gov (NCT)

NCT00179777

Protocol serial number

MCT-49395

# Study information

#### Scientific Title

Trial to Reduce Insulin dependent diabetes mellitus in the Genetically at Risk: a randomised controlled trial

#### Acronym

**TRIGR** 

#### **Study objectives**

The hypothesis for this proposal holds that weaning to an extensively hydrolysed infant formula will decrease the incidence of type I diabetes, as it does in all relevant animal models for the disease.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

- 1. The Hospital District of Helsinki and UUSIMAA, Finland, 19/09/2000
- 2. The Ethical Committee of Paediatrics and Psychiatry, London Health Sciences Centre, London, Ontario, 02/05/2002

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Study type(s)

Prevention

## Health condition(s) or problem(s) studied

Type 1 Diabetes Mellitus

#### **Interventions**

Experimental Arm:

Use of infant feed formula, cow milk based, extensively hydrolysed administered when needed in supplementation or substitution for breast milk through 6 - 8 months from birth. (Formulated by MeadJohnson)

#### Control Arm:

Use of infant feed formula, cow milk based, non-hydrolysed administered when needed in supplementation or substitution for breast milk through 6 - 8 months from birth. (Formulated by MeadJohnson)

Trial details received: 12 Sept 2005

#### Intervention Type

Drug

#### Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Infant feed formulas

#### Primary outcome(s)

Development of diabetes mellitus

#### Key secondary outcome(s))

- 1. Development of diabetes associated islet antibodies ICA, IAA, GADA Abs, IA-2A Abs
- 2. Development of cow milk protein antibodies

#### Completion date

31/05/2016

# Eligibility

#### Key inclusion criteria

- 1. The biological parents and/or full (not half) sibling of the newborn infant has type 1 diabetes as defined by the World Health Organization
- 2. The infants parents or legal guardians give signed consent to participate

#### Participant type(s)

Patient

#### Healthy volunteers allowed

No

#### Age group

Other

#### Sex

ΔII

#### Kev exclusion criteria

- 1. An older sibling of the newborn infant has been included in the TRIGR intervention
- 2. Multiple gestation
- 3. The parents are unwilling or unable to feed the infant cows milk based products for any reason (e.g. religious, cultural)
- 4. The newborn infant has a recognisable severe illness such as those due to chromosomal abnormality, congenital malformation, respiratory failure needing assisted ventilation, enzyme deficiencies etc.
- 5. The gestational age of the newborn infant is less than 35 weeks
- 6. The infant is older than 7 days at randomisation
- 7. Inability of the family to take part in the study (e.g. the family has no access to any of the Study Centres, the family has no telephone)
- 8. The infant has received any infant formula other than Nutramigen prior to randomisation
- 9. No HLA sample drawn before the age of 8 days

#### Date of first enrolment

01/03/2002

# Date of final enrolment 31/05/2016

# **Locations**

# **Countries of recruitment** Australia

Canada

Czech Republic

Estonia

**Finland** 

Germany

Hungary

Italy

Luxembourg

Netherlands

**Poland** 

**Spain** 

Sweden

**Switzerland** 

United States of America

Study participating centre John P. Robarts Research Institute London Canada N6A 5K8

# Sponsor information

# Organisation

John P. Robarts Research Institute (Canada)

#### **ROR**

https://ror.org/02grkyz14

# Funder(s)

#### Funder type

Research organisation

#### **Funder Name**

Canadian Institutes of Health Research (CIHR) (Canada), ref: MCT-49395

#### Alternative Name(s)

Instituts de Recherche en Santé du Canada, Canadian Institutes of Health Research (CIHR), CIHR\_IRSC, Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

#### Funding Body Type

Government organisation

#### **Funding Body Subtype**

National government

#### Location

Canada

#### **Funder Name**

**US Congress (USA)** 

#### **Funder Name**

National Institute of Child health and Human Development (NICHD) (USA)

#### Alternative Name(s)

**NICHD** 

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

National government

#### Location

United States of America

#### Funder Name

Juvenile Diabetes Research Foundation (JDRF) (Direct) (UK)

#### **Funder Name**

European Foundation for the Study of Diabetes (EFSD)/JDRF/Novo Nordisk

#### **Funder Name**

Finnish Diabetes Research Foundation (Finland)

#### **Funder Name**

Academy of Finland (Finland)

#### Alternative Name(s)

Academy of Finland, Suomen Akatemia, Finlands Akademi, AKA

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

Research institutes and centers

#### Location

Finland

#### **Funder Name**

Dutch Diabetes Research Foundation (Netherlands)

#### Alternative Name(s)

**Dutch Diabetes Research Foundation** 

#### **Funding Body Type**

Private sector organisation

#### **Funding Body Subtype**

Trusts, charities, foundations (both public and private)

#### Location

Netherlands

## Funder Name

European Union (EU)

# **Results and Publications**

# Individual participant data (IPD) sharing plan

## IPD sharing plan summary

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
Results article	results	02/01/2018	12/04 /2019	Yes	No
Protocol article	protocol	01/06/2007		Yes	No
Other publications	recruitment and retention strategies	01/04/2014		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11 /2025	No	Yes
Study website	Study website	11/11/2025	11/11 /2025	No	Yes